Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis

Pathology

Volumn 45, Issue 4, 2013, Pages 371-381

  Hemmings, Chris ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Angiogenesis; Carcinogenesis; Epithelial mesenchymal transition; Extracellular matrix; Fibrosis; Inflammation; Stem cell niche; Stroma; Tumour microenvironment

Indexed keywords

EID: 84879613680     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328360b600     Document Type: Article

References (122)

1. Bhowmick N, Neilson E, Moses H. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
2. Camacho D, Plenta K. Disrupting the networks of cancer. Clin Cancer Res 2012; 18: 2801-8.
3. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32.
4. Orimo A, Gupta P, Sgroi D, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CSCL12 secretion. Cell 2005; 121: 335-48.
5. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
6. Oladipo O, Conlon S, O'Grady A, et al. The expression and prognostic impact of CXC-chemokines in Stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 2011; 104: 480-7.
7. Lee Y, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012; 106: 1833-41.
8. Nishida N, Nagahara M, Sato T, et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res 2012; 18: 3054-70.
9. Howe J, Roth S, Ringold J, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280: 1086-8.
10. Sneddon J, Werb Z. Location, location, location: The cancer stem cell niche. Cell Stem Cell 2007; 1: 607-11.
11. Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumours and field cancerisation from loss of mesenchymal CSL signalling. Cell 2012; 149: 1207-20.
12. Hemmings C. The elaboration of a critical framework for understanding cancer: The cancer stem cell hypothesis. Pathology 2010; 42: 105-12.
13. Guilak F, Cohen D, Estes B, et al. Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell 2009; 5: 17-26.
14. Cabarcas S, Mathews L, Farra W. The cancer stem cell niche - there goes the neighbourhood? Int J Cancer 2011; 129: 2315-27.
15. Allen M, Jones J. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J Pathol 2011; 223: 162-76.
16. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-41.
17. Galli R, Borello U, Gritti A, et al. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci 2000; 3: 986-91.
18. Chao C, Carmical J, Ives K, et al. CD133 colon cancer cells are more interactive with the tumor microenvironment than CD133- cells. Lab Invest 2012; 92: 420-36.
19. Voog J, Jones D. Stem cells and the niche: A dynamic duo. Cell Stem Cell 2010; 6: 103-15.
20. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-cell like cells give rise to tumour epithelium. Nature 2010; 468: 829-33.
21. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-8.
22. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumour stem cells. Cancer Cell 2007; 11: 69-82.
23. Charles N, Ozawa T, Squatrito M, et al. Perivascular nitric oxide activates Notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010; 6: 141-52.
24. Loebinger M, Sage E, Davies D, Hanes S. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 2010; 103: 1692-7.
25. Klymkowsky M, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588-93.
26. Thiery J, Sleeman J. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-42.
27. Zavadil J, Bottinger E. TGF-beta and epithelial-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
28. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
29. Chai J, Norng M, Modak C, et al. CCN1 induces a reversible epithelialmesenchymal transition in gastric epithelial cells. Lab Invest 2010; 90: 1140-51.
30. Matise L, Palmer T, Ashby W, et al. Lack of transforming growth factorbeta signaling promotes collective cancer cell invasion through tumorstromal crosstalk. Breast Cancer Res 2012; 14: R98.
31. Mani S, Guo W, Liao M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
32. Dave B, Mittal V, Tan N, Chang J. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012; 14:202.
33. Radisky D, LaBarge M. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008; 2: 511-2.
34. Yang M, Hsu D, Wang H, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nature Cell Biol 2010; 12: 982-92.
35. Olumi A, Grossfield G, Hayward S, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
36. Kopantzev E, Vayshiya N, Kopantseva M, et al. Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas. Br J Cancer 2010; 102: 1533-40.
37. Bhowmick N, Chytil A, Plieth D, et al. TGF-b signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51.
38. Shao H, Cai L, Grichnik J, et al. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 2011; 30: 4316-26.
39. Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; 18: 1359-68.
40. Dvorak H. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
41. West R, van de Rijn M. Experimental approaches to the study of cancerstroma interactions: Recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 2007; 87: 967-70.
42. West R, Nuyten D, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005; 3: E187.
43. Wu J, Beck A, Pate L, et al. Endogenous versus tumor-specific host response to breast carcinoma: A study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res 2011; 17: 437-46.
44. Chang H, Sneddon J, Alizadeh A, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
45. Chang H, Dimitry S, Nuyten A, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-43.
46. Lieubeau B, Garrigue L, Barbieux I, Meflah K, Gregoire M. The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 1994; 54: 6526-32.
47. Dvorak H, Dvorak A, Manseau E, Wiberg L, Churchill W. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 1979; 62: 1459-72.
48. Barsky S, Gopalakrishna R. Increased invasion and spontaneous metastasis of BL6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res 1987; 47: 1663-7.
49. Peyrol S, Raccurt M, Gerard F, et al. Lysyl oxidase gene expression in the stromal reaction to the in situ and invasive ductal breast carcinoma. Am J Pathol 1997; 150: 497-507.
50. Elenbaas B, Weinberg R. Heterotypic signaling between epithelial tumor cells and fibroblasts in cancer formation. Exp Cell Res 2001; 264: 169-84.
51. Beck A, Espinosa I, Gilds C, van de Rijn M, West R. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 2008; 88: 591-601.
52. Beck A, Espinosa I, Edris B, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009; 15: 778-87.
53. Sharma M, Beck A, Webster J, et al. Analysis of stromal signatures in the tumor microenvironment of Ductal Carcinoma In Situ. Breast Cancer Res Treat 2010; 123: 397-404.
54. Webster J, Beck A, Sharma M, et al. Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol 2010; 222: 158-65.
55. Bianchini G, Qi Y, Alvarez R, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010; 28: 4316-23.
56. Provenzano P, Eliceiri K, Campbell J, et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006; 4: 38.
57. Moorman A, Vink R, Heijmans H, van der Palen J, Kouwenhoven E. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 2012; 38: 307-13.
58. Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer 2011; 2: 1139-45.
59. Tai T, Tang M. SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist Updat 2008; 11: 231-46.
60. Chlenski A, Guerrero L, Yang Q, et al. SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene 2007; 26: 4513-22.
61. Tang M, Tai I. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 2007; 47: 34457-6.
62. Taghizadeh F, Tang M, Tai I. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther 2007; 6: 309-17.
63. Buraschi S, Neill T, Owens RT, et al. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triplenegative orthotopic breast carcinoma xenograft model. PLoS One 2012; 7: e45559.
64. Neill T, Painter H, Buraschi S, et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1a, vascular endothelial growth factor A, and induction of thrombospondin- 1 and TIMP3. J Biol Chem 2012; 287: 5492-506.
65. Sun X, Zhang H. Clinicopathological significance of stromal variables: Angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 2006; 5: 43.
66. Liss M, Sreedhar N, Keshgegian A, et al. Tissue inhibitor of Metalloproteinase- 4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol 2009; 175: 940-6.
67. Blackburn J, Lui I, Coon C, Brinckerhoff C. A matrix metalloproteinase-1/ protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009; 28: 4237-48.
68. Langers A, Verspaget H, Hawinkels L, et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer 2012; 106: 1495-8.
69. Ye Q, Yan Z, Liao X, et al. MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest 2011; 91: 778-87.
70. Boxler S, Djonov V, Kessler T, et al. Matrix metalloproteinases and angiogenic factors: Predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol 2010; 177: 2216-24.
71. Behrens P, Mathiak M, Mangold E. Stromal expression of invasionpromoting, matrix-degrading proteases MMP-1 and -9 and the Ets transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 2003; 107: 183-8.
72. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
73. Moller Sorensen N, Veigaard Sorensen I, Ornbjerg Wurtz S, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases- 1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43: 774-86.
74. Zheng G, Lyons J, Tan T, et al. Disruption of e-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transformation growth factor-b1 in renal tubular epithelial cells. Am J Pathol 2009; 175: 580-91.
75. Hojilla C, Mohammed F, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-21.
76. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008;45: 291-338.
77. Fiore E, Rusco C, Romero P, Stamenkovic I. Matrix metalloproteinase 9 (MMP9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002; 21: 5213-23.
78. Sheu B, Hsu S, Ho H, et al. A novel role of metalloproteinase in cancermediated immunosuppression. Cancer Res 2001; 61: 237-42.
79. Fridman W, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
80. Roxburgh C, Salmond J, Horgan P, Oien K, McMillan D. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45: 2138-45.
81. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-51.
82. Dahlin A, Henriksson M, van Guelpen B, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011; 24: 671-82.
83. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
84. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8.
85. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-71.
86. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010; 28: 4045-51.
87. Pages F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautes-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29: 1093-102.
88. Gilbert L, Hemann M. DNA damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-66.
89. Maniati E, Soper R, Hagemann T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010; 29: 5653-62.
90. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-53.
91. Merlo A, Casalini P, Carcangiu M, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009; 27: 2746-52.
92. deLeeuw R, Kost S, Kakal J, Nelson B. The prognostic value of FoxP3 tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin Cancer Res 2012; 18: 3022-9.
93. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 2009; 24: 1565-75.
94. Kroge Jensen H, Donskov F, Marcussen N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-17.
95. Young M, Lathers D. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999; 21: 241-52.
96. Almand B, Clark J, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-89.
97. Toh B, Wang X, Keeble J, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011; 9: e1001162.
98. Yang L, deBusk L, Fukuda K, et al. Expansion of myeloid immune suppressor GrCD11b cells in tumour-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-21.
99. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1CD11b myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
100. Buddingh E, Kuijjer M, Duim R, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin Cancer Res 2010; 17: 2110-9.
101. Qian B, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
102. Gocheva V, Wang H, Gadea B, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010; 24: 241-55.
103. Chao M, Weissman I, Majeti R. The CD47-SIRPa pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012; 24: 225-32.
104. de Palma M, Clewis C. Macrophages limit chemotherapy. Nature 2011; 472: 303-4.
105. Proctor M, Morrison D, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104: 726-34.
106. Richards C, Leitch E, Horgan P, et al. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer 2010; 103: 1356-61.
107. Roxburgh C, McDonald A, Salmond J, et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis 2011; 26: 483-92.
108. de Visser K, Eichten A, Coussens L. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
109. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-23.
110. Grivvenikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
111. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
112. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22: 251-6.
113. Gao D, Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 2009; 15: 333-43.
114. Mc Allister S, Weinberg R. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010; 28: 4022-8.
115. Worthley D, Ruszkiewic A, Davies R, et al. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrowderived cells following allogeneic stem cell transplantation. Stem Cells 2009; 27: 1463-8.
116. Koeneman K, Yeung F, Chung L. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-61.
117. Corn P. The tumour microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Management Res 2012; 4: 183-93.
118. Josson S, Matsuoka Y, Chung L, Zhau H, Wang R. Tumor-stroma coevolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 2010; 21: 26-32.
119. Castellano D, Sepulveda J, Garcia-Escobar I, et al. The role of RANKligand inhibition in cancer: The story of denosumab. Oncologist 2011; 16: 136-45.
120. Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011; 481: 85-9.
121. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165-78.
122. McAllister S, Gifford A, Greiner A, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.